$CELG Company News Liquid growth stocks tell i
Post# of 89397
Posted On: 12/12/2014 11:41:37 AM
$CELG Company News
Liquid growth stocks tell interesting tale 3:11 p.m. Dec. 9, 2014 - The Trading Deck
H&R Block shares fall on quarterly miss 6:42 p.m. Dec. 8, 2014 - Wallace Witkowski
The S&P 500 recorded its biggest drop in nearly 7 weeks 4:33 p.m. Dec. 8, 2014 - Anora Mahmudova
Celgene shares climb 1.9% 9:31 a.m. Dec. 8, 2014 - Sue Chang
Is the next Cisco out there? 3:24 p.m. Nov. 25, 2014 - The Trading Deck
5 charts show how stock repurchases boost prices 6:00 a.m. Nov. 18, 2014 - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 3:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 10:59 a.m. July 17, 2014 - The Trading Deck
Celgene Takes Over #14 Spot From Edison International 12:52 p.m. Dec. 11, 2014 - TheStreet.com
Celgene's Abraxane Succeeds In Early Breast Cancer 10:27 a.m. Dec. 11, 2014 - Investors Business Daily
Tell Me How You Really Feel: A Look At The Market Through Analyst Consensus Recommendations 8:02 a.m. Dec. 11, 2014 - Seeking Alpha
Cramer's Mad Money - The Good Isis (12/10/14) 4:43 a.m. Dec. 11, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: The Good News-Bad News of Lower Oil Prices 8:41 p.m. Dec. 10, 2014 - TheStreet.com
How To Invest: Don't Mix CAN SLIM With Other Systems 5:09 p.m. Dec. 10, 2014 - Investors Business Daily
Adaptive Asset Allocation: Experimentation With A Large Stock Portfolio 1:53 p.m. Dec. 10, 2014 - Seeking Alpha
Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More 12:17 p.m. Dec. 10, 2014 - Seeking Alpha
Stock Market News for December 10, 2014 - Market News 10:10 a.m. Dec. 10, 2014 - Zacks.com
Are Investors Signaling Optimism in Biotechs Through Short Interest? 9:24 a.m. Dec. 10, 2014 - 247WallSt.com
Celgene Up on Positive Revlimid Data Presented at ASH - Analyst Blog 4:40 p.m. Dec. 9, 2014 - Zacks.com
Bluebird Bio Stock Spikes On New Blood Treatment 1:10 p.m. Dec. 9, 2014 - Investors Business Daily
Multiple myeloma patients have a rough time with Celgene's pomalidomide 8:28 a.m. Dec. 9, 2014 - Seeking Alpha
Top Analyst Upgrades and Downgrades: Cisco, DreamWorks, Lululemon, Nabors, Schlumberger, Verizon and More 7:51 a.m. Dec. 9, 2014 - 247WallSt.com
Amgen Unveils Positive Results from Blood Cancer Studies - Analyst Blog 7:05 p.m. Dec. 8, 2014 - Zacks.com
Agios (AGIO) Reports Encouraging Data on Leukemia Drug - Analyst Blog 4:35 p.m. Dec. 8, 2014 - Zacks.com
Stocks Are Dragged Lower as Oil Prices Plunge to 5-Year Low 4:24 p.m. Dec. 8, 2014 - TheStreet.com
Stocks Recover From Session Lows Though Oil Prices Continue to Hurt 3:30 p.m. Dec. 8, 2014 - TheStreet.com
Celgene, Acceleron Pharma Report Prelim. Data from Ongoing Phase 2 Trials in Patients with Lower Risk MDS:: Luspatercept, Sotatercept Increased Hemoglobin Levels 1:04 p.m. Dec. 8, 2014 - benzinga.com
Celgene Offers Results from Phase III Study of REVLIMID, Showed Improved Transfusion Independence 12:51 p.m. Dec. 8, 2014 - benzinga.com
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers 8:00 a.m. Nov. 20, 2014 - BusinessWire - BZX
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV 4:29 p.m. Nov. 19, 2014 - Marketwired
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV 3:35 p.m. Nov. 19, 2014 - Marketwired
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 7:35 a.m. Oct. 20, 2014 - BusinessWire - BZX
Liquid growth stocks tell interesting tale 3:11 p.m. Dec. 9, 2014 - The Trading Deck
H&R Block shares fall on quarterly miss 6:42 p.m. Dec. 8, 2014 - Wallace Witkowski
The S&P 500 recorded its biggest drop in nearly 7 weeks 4:33 p.m. Dec. 8, 2014 - Anora Mahmudova
Celgene shares climb 1.9% 9:31 a.m. Dec. 8, 2014 - Sue Chang
Is the next Cisco out there? 3:24 p.m. Nov. 25, 2014 - The Trading Deck
5 charts show how stock repurchases boost prices 6:00 a.m. Nov. 18, 2014 - Ophir Gottlieb
The double-edged sword of growth-stock speculation 2:30 p.m. Nov. 14, 2014 - The Trading Deck
Two biotech leaders to watch 1:13 p.m. Oct. 28, 2014 - The Trading Deck
Celgene profit up 37%, raises outlook 7:42 a.m. Oct. 23, 2014 - MarketWatch.com
Be ready to play another market surge 11:25 a.m. Sept. 19, 2014 - The Trading Deck
14 stocks loved by top-performing fund managers 5:49 a.m. Sept. 18, 2014 - Philip van Doorn
Lululemon surges; RadioShack rebounds 2:24 p.m. Sept. 11, 2014 - Sue Chang
Major U.S. benchmarks rattle cage on first support 10:06 a.m. Sept. 10, 2014 - Michael Ashbaugh
Celgene shares up on news of positive late-stage drug trial 6:42 a.m. Sept. 4, 2014 - Ciara Linnane
How retail sector sets up stocks at the end of summer 2:32 p.m. Aug. 14, 2014 - The Trading Deck
S&P 500 retests the breakdown point 10:17 a.m. Aug. 14, 2014 - Michael Ashbaugh
S&P 500 ekes out another record close: stock market live blog recap 3:03 p.m. July 24, 2014 - blogs.marketwatch.com
Biotechs beat estimates, but the Street wants more 10:44 a.m. July 24, 2014 - Russ Britt
Biogen results crush consensus 3:55 p.m. July 23, 2014 - The Trading Deck
Nasdaq needs to turn up the volume 10:59 a.m. July 17, 2014 - The Trading Deck
Celgene Takes Over #14 Spot From Edison International 12:52 p.m. Dec. 11, 2014 - TheStreet.com
Celgene's Abraxane Succeeds In Early Breast Cancer 10:27 a.m. Dec. 11, 2014 - Investors Business Daily
Tell Me How You Really Feel: A Look At The Market Through Analyst Consensus Recommendations 8:02 a.m. Dec. 11, 2014 - Seeking Alpha
Cramer's Mad Money - The Good Isis (12/10/14) 4:43 a.m. Dec. 11, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: The Good News-Bad News of Lower Oil Prices 8:41 p.m. Dec. 10, 2014 - TheStreet.com
How To Invest: Don't Mix CAN SLIM With Other Systems 5:09 p.m. Dec. 10, 2014 - Investors Business Daily
Adaptive Asset Allocation: Experimentation With A Large Stock Portfolio 1:53 p.m. Dec. 10, 2014 - Seeking Alpha
Allergan Leads The 20 Best Value Bond Trades With A Maturity Of 1 Year Or More 12:17 p.m. Dec. 10, 2014 - Seeking Alpha
Stock Market News for December 10, 2014 - Market News 10:10 a.m. Dec. 10, 2014 - Zacks.com
Are Investors Signaling Optimism in Biotechs Through Short Interest? 9:24 a.m. Dec. 10, 2014 - 247WallSt.com
Celgene Up on Positive Revlimid Data Presented at ASH - Analyst Blog 4:40 p.m. Dec. 9, 2014 - Zacks.com
Bluebird Bio Stock Spikes On New Blood Treatment 1:10 p.m. Dec. 9, 2014 - Investors Business Daily
Multiple myeloma patients have a rough time with Celgene's pomalidomide 8:28 a.m. Dec. 9, 2014 - Seeking Alpha
Top Analyst Upgrades and Downgrades: Cisco, DreamWorks, Lululemon, Nabors, Schlumberger, Verizon and More 7:51 a.m. Dec. 9, 2014 - 247WallSt.com
Amgen Unveils Positive Results from Blood Cancer Studies - Analyst Blog 7:05 p.m. Dec. 8, 2014 - Zacks.com
Agios (AGIO) Reports Encouraging Data on Leukemia Drug - Analyst Blog 4:35 p.m. Dec. 8, 2014 - Zacks.com
Stocks Are Dragged Lower as Oil Prices Plunge to 5-Year Low 4:24 p.m. Dec. 8, 2014 - TheStreet.com
Stocks Recover From Session Lows Though Oil Prices Continue to Hurt 3:30 p.m. Dec. 8, 2014 - TheStreet.com
Celgene, Acceleron Pharma Report Prelim. Data from Ongoing Phase 2 Trials in Patients with Lower Risk MDS:: Luspatercept, Sotatercept Increased Hemoglobin Levels 1:04 p.m. Dec. 8, 2014 - benzinga.com
Celgene Offers Results from Phase III Study of REVLIMID, Showed Improved Transfusion Independence 12:51 p.m. Dec. 8, 2014 - benzinga.com
Data Presented on REVLIMID® (lenalidomide) Compared with Investigators’ Choice in Relapsed/Refractory Diffuse Large B-Cell Lymphoma 8:34 p.m. Dec. 8, 2014 - BusinessWire - BZX
Additional Analyses of High-Risk Patients from Phase III Study (AML-001) OF Vidaza® (Azacitidine for Injection) in Acute Myeloid Leukemia Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
REVLIMID® (Lenalidomide) Single-Agent and Combination Studies in Mantle Cell Lymphoma (MCL) Presented at ASH 8:33 p.m. Dec. 8, 2014 - BusinessWire - BZX
New Data in Myelodysplastic Syndromes Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition 2:00 p.m. Dec. 8, 2014 - BusinessWire - BZX
Results from Phase III Study of REVLIMID® (Lenalidomide) Demonstrating Improved Transfusion Independence in Patients with Rare Blood Cancer, Non-Del-5Q Myelodysplastic Syndromes (MDS), Presented at ASH 1:49 p.m. Dec. 8, 2014 - BusinessWire - BZX
Age, Renal Impairment and Depth of Response Analyses of the FirstTM (MM-020/IFM 07-01)Study of Continuous REVLIMID® (lenalidomide) Plus Low-Dose dexamethasone in Newly-Diagnosed Multiple Myeloma Presented at ASH 9:58 p.m. Dec. 7, 2014 - BusinessWire - BZX
Critical Alerts For Noodles & Company, Goldcorp, YY, Celgene and LinkedIn Released By InvestorsObserver 9:31 a.m. Dec. 2, 2014 - PR Newswire - PRF
Celgene Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Corporation 4:30 p.m. Dec. 1, 2014 - BusinessWire - BZX
Celgene Receives Positive CHMP Opinion for OTEZLA® (apremilast), the First Oral PDE4 Inhibitor for the Treatment of Patients with Psoriasis and Psoriatic Arthritis 6:00 a.m. Nov. 21, 2014 - BusinessWire - BZX
Chef Michael Ferraro, the Pancreatic Cancer Action Network and Meals to Heal Team up with Celgene to Address Nutritional Needs and Challenges Faced by Pancreatic Cancer Patients and Caregivers 8:00 a.m. Nov. 20, 2014 - BusinessWire - BZX
UPDATE: Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Well Tolerated and Increases CD4 Counts in People Living With HIV 4:29 p.m. Nov. 19, 2014 - Marketwired
Bionor Pharma Announces That the Combination of Vacc-4x + Revlimid(R) Is Safe and Increases CD4 Counts in People Living With HIV 3:35 p.m. Nov. 19, 2014 - Marketwired
Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis 7:30 a.m. Nov. 18, 2014 - BusinessWire - BZX
Moffitt Cancer Center Announces Development of Experimental Treatment for Myelodysplastic Syndromes, Autoimmune Diseases 9:03 a.m. Nov. 17, 2014 - BusinessWire - BZX
Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene 9:10 a.m. Nov. 14, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Critical Alerts For Alibaba, Bloomin' Brands, VoxelJet, 51job and Celgene Released By InvestorsObserver 9:31 a.m. Nov. 5, 2014 - PR Newswire - PRF
Celgene Corporation to Webcast at Upcoming Investor Conferences and Medical Congress 8:30 a.m. Oct. 31, 2014 - BusinessWire - BZX
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Phase II Data in Crohn’s Disease for Celgene’s Oral Antisense Therapy GED-0301 to Be Presented at UEG Week 2014 7:35 a.m. Oct. 20, 2014 - BusinessWire - BZX
(0)
(0)